Dashboard
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 1.56%
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 2.15
Flat results in Sep 26
Stock is technically in a Mildly Bearish range
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Healthcare Services
INR 30 Cr (Micro Cap)
16.00
40
0.00%
0.08
1.82%
0.25
Total Returns (Price + Dividend) 
Deccan Healthcar for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Deccan Health Care Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals
Deccan Health Care Ltd has been downgraded from a Sell to a Strong Sell rating as of 23 Oct 2026, reflecting deteriorating technical indicators and stagnant financial performance. Despite a very attractive valuation, the company’s weak quality metrics and persistent underperformance against benchmarks have raised significant concerns for investors.
Read More
Deccan Health Care Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals
Deccan Health Care Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 09 Oct 2026, driven primarily by a shift in technical indicators despite ongoing fundamental challenges. The micro-cap healthcare services company’s technical trend has improved from bearish to mildly bearish, prompting a reassessment of its market stance. However, the company continues to face flat financial performance and persistent underperformance relative to benchmarks, keeping its overall Mojo Grade at a cautious Sell.
Read More
Deccan Health Care Ltd is Rated Strong Sell
Deccan Health Care Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 08 October 2026, providing investors with the latest perspective on the company’s position.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
16-Nov-2026 | Source : BSENewspaper Publication
Board Meeting Outcome for Outcome Of Board Meeting
13-Nov-2026 | Source : BSEPursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015 please find enclosed herewith the Un-Audited Financial Results (Standalone & Consolidated) for the quarter & half year ended 30.09.2026 along with Limited Review Report by Statutory Auditor i.e. Keyur Shah & Associates Chartered Accountants.
Board Meeting Intimation for Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30Th 2026
06-Nov-2026 | Source : BSEDeccan Health Care Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 inter alia to consider and approve the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30th 2026
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Minto Purshotam Gupta (14.03%)
Focal Ventures Private Limited (11.89%)
52.73%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 24.42% vs 5.20% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 37.93% vs -12.12% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 28.51% vs 19.21% in Sep 2024
Growth in half year ended Sep 2025 is 29.21% vs 5.95% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 12.19% vs 24.11% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 108.74% vs -24.82% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 9.11% vs 25.67% in Mar 2025
YoY Growth in year ended Mar 2026 is 114.66% vs -22.15% in Mar 2025